Amazon Pharmacy debuts RxPass: unlimited Rx generics for only $5 a month

25 January 2023
amazon_big

US tech giant Amazon (Nasdaq: AMZN) has announced RxPass, a new Prime membership benefit from Amazon Pharmacy that offers patients affordable access to commonly prescribed generic medications that treat more than 80 common health conditions.

With RxPass, Prime members can receive all of their eligible medications for one flat, low monthly fee of $5, and have them delivered free of charge. There are no hidden fees and no markups to the $5 per month subscription. RxPass is available starting today in most U.S. states.

Amazon has pushed deeper into health care in recent years. The company launched its own online pharmacy in 2020, a service that was born out of its acquisition of PillPack in 2018. It also announced that it would acquire boutique primary care provider One Medical.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Generics